228 results on '"Lønning, Per E."'
Search Results
2. Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions
3. Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
4. C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer
5. Constitutional BRCA1 Epimutations: A Key for Understanding Basal‐Like Breast and High‐Grade Serous Ovarian Cancer.
6. A national precision cancer medicine implementation initiative for Norway
7. Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?
8. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
9. Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets
10. Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors
11. Assessment of tumor suppressor promoter methylation in healthy individuals
12. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC
13. White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
14. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
15. APOBEC3A/B deletion polymorphism and endometrial cancer risk.
16. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer
17. The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians
18. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
19. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon
20. Vascular proliferation is a prognostic factor in breast cancer
21. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique
22. Mutation of GATA3 in human breast tumors
23. Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators
24. Aromatase Inhibitors and Inactivators for Breast Cancer Therapy
25. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
26. Molecular portraits of human breast tumours
27. Is There a Growing Role for Endocrine Therapy in the Treatment of Breast Cancer?
28. Recent data on intratumor estrogens in breast cancer
29. Molecular basis for therapy resistance
30. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer
31. Pharmacological and clinical profile of anastrozole
32. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer
33. Paclitaxel and Docetaxel: Innovation, But at What Cost?
34. Plasma changes in breast cancer patients during endocrine therapy — lipid measurements and nuclear magnetic resonance (NMR) spectroscopy
35. Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer?
36. Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines
37. Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
38. Aromatase inhibitors in the treatment of early and advanced breast cancer
39. Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
40. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer
41. Endocrine Effects of Nonsteroidal Aromatase Inhibitors and Their Clinical Impact
42. Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer.
43. Exemestane: A Viewpoint by Per E. Lønning
44. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
45. Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters
46. Exemestane in Breast Cancer: Current Status and Future Directions
47. Long-Term Follow-Up of the Intergroup Exemestane Study.
48. Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells.
49. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
50. Prevalence of the CHEK2 R95* germline mutation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.